Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study.

Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G.

Support Care Cancer. 2019 Jan 19. doi: 10.1007/s00520-018-4632-0. [Epub ahead of print]

PMID:
30661202
2.

Addressing the Symptom Management Gap in Patients With Cancer and Heart Failure Using the Interactive Voice Response System: A Pilot Study.

Fadol AP, Mendoza TR, Lenihan DJ, Berry DL.

J Adv Pract Oncol. 2018 Mar;9(2):201-214. Epub 2018 Mar 1. Review.

3.

Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies.

Mendoza TR.

Adv Exp Med Biol. 2018;995:165-182. doi: 10.1007/978-3-030-02505-2_9.

PMID:
30539512
4.

Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events.

Atkinson TM, Reeve BB, Dueck AC, Bennett AV, Mendoza TR, Rogak LJ, Basch E, Li Y.

J Patient Rep Outcomes. 2018 Dec 4;2(1):56. doi: 10.1186/s41687-018-0086-x.

5.

Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Williams LA, Whisenant MS, Mendoza TR, Haq S, Keating KN, Cuffel B, Cleeland CS.

Qual Life Res. 2018 Dec;27(12):3229-3241. doi: 10.1007/s11136-018-1982-5. Epub 2018 Sep 5. Review.

PMID:
30187393
6.

Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS).

Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS.

Support Care Cancer. 2019 Mar;27(3):1021-1028. doi: 10.1007/s00520-018-4391-y. Epub 2018 Aug 10.

PMID:
30094731
7.

Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study.

Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, Schrag D, Dueck AC, Abernethy AP.

JMIR Hum Factors. 2018 Jul 16;5(3):e10070. doi: 10.2196/10070.

8.

The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning.

Mendoza TR, Osei J, Duvic M.

J Investig Dermatol Symp Proc. 2018 Jan;19(1):S41-S46. doi: 10.1016/j.jisp.2017.10.009.

9.

Patient reported dry mouth: Instrument comparison and model performance for correlation with quality of life in head and neck cancer survivors.

MD Anderson Head and Neck Cancer Symptom Working Group, Kamal M, Rosenthal DI, Volpe S, Goepfert RP, Garden AS, Hutcheson KA, Al Feghali KA, Meheissen MAM, Eraj SA, Dursteler AE, Williams B, Smith JB, Aymard JM, Berends J, White AL, Frank SJ, Morrison WH, Cardoso R, Chambers MS, Sturgis EM, Mendoza TR, Lu C, Mohamed ASR, Fuller CD, Gunn GB.

Radiother Oncol. 2018 Jan;126(1):75-80. doi: 10.1016/j.radonc.2017.10.037. Epub 2017 Dec 8.

10.

Correction to: Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Brandon Gunn G.

Radiat Oncol. 2017 Nov 23;12(1):186. doi: 10.1186/s13014-017-0921-x.

11.

What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales.

Atkinson TM, Hay JL, Dueck AC, Mitchell SA, Mendoza TR, Rogak LJ, Minasian LM, Basch E.

J Pain Symptom Manage. 2018 Mar;55(3):e3-e6. doi: 10.1016/j.jpainsymman.2017.10.024. Epub 2017 Nov 10. No abstract available.

12.

The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials.

Mendoza TR, Dueck AC, Shi Q, Ma H, Zhang J, Qian Y, Cleeland CS.

Eur J Pain. 2018 Mar;22(3):565-571. doi: 10.1002/ejp.1139. Epub 2017 Oct 30.

PMID:
29082574
13.

Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.

MD Anderson Head and Neck Cancer Symptom Working Group, Eraj SA, Jomaa MK, Rock CD, Mohamed ASR, Smith BD, Smith JB, Browne T, Cooksey LC, Williams B, Temple B, Preston KE, Aymard JM, Gross ND, Weber RS, Hessel AC, Ferrarotto R, Phan J, Sturgis EM, Hanna EY, Frank SJ, Morrison WH, Goepfert RP, Lai SY, Rosenthal DI, Mendoza TR, Cleeland CS, Hutcheson KA, Fuller CD, Garden AS, Gunn GB.

Radiat Oncol. 2017 Sep 9;12(1):150. doi: 10.1186/s13014-017-0878-9. Erratum in: Radiat Oncol. 2017 Nov 23;12 (1):186.

14.

Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.

Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E.

Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.

15.

Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients.

Majedi H, Dehghani SS, Soleyman-Jahi S, Emami Meibodi SA, Mireskandari SM, Hajiaghababaei M, Tafakhori A, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2017 Jul;54(1):132-138.e2. doi: 10.1016/j.jpainsymman.2017.02.017. Epub 2017 May 4.

PMID:
28479416
16.

Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.

Basch E, Pugh SL, Dueck AC, Mitchell SA, Berk L, Fogh S, Rogak LJ, Gatewood M, Reeve BB, Mendoza TR, O'Mara AM, Denicoff AM, Minasian LM, Bennett AV, Setser A, Schrag D, Roof K, Moore JK, Gergel T, Stephans K, Rimner A, DeNittis A, Bruner DW.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):409-418. doi: 10.1016/j.ijrobp.2017.02.002. Epub 2017 Feb 10.

17.

Determination of mild, moderate, and severe pain interference in patients with cancer.

Shi Q, Mendoza TR, Dueck AC, Ma H, Zhang J, Qian Y, Bhowmik D, Cleeland CS.

Pain. 2017 Jun;158(6):1108-1112. doi: 10.1097/j.pain.0000000000000890.

PMID:
28267060
18.

Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.

George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS.

Cancer. 2016 Nov 15;122(21):3401-3409. doi: 10.1002/cncr.30182. Epub 2016 Jul 14.

19.

Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients.

Paramita N, Nusdwinuringtyas N, Nuhonni SA, Atmakusuma TD, Ismail RI, Mendoza TR, Cleeland CS.

J Pain Symptom Manage. 2016 Nov;52(5):744-751. doi: 10.1016/j.jpainsymman.2016.04.011. Epub 2016 Sep 19.

PMID:
27660081
20.

Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer.

Shi Q, Mendoza TR, Wang XS, Cleeland CS.

Eur J Cancer. 2016 Nov;67:83-90. doi: 10.1016/j.ejca.2016.07.027. Epub 2016 Sep 9.

PMID:
27620946
21.

Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes.

Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1107-14. doi: 10.1016/j.ijrobp.2016.02.044. Epub 2016 Feb 18.

22.

Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module.

Gunn GB, Atalar B, Mendoza TR, Cleeland CS, Selek U, Özyar E, Rosenthal DI.

Balkan Med J. 2016 May;33(3):339-43. doi: 10.5152/balkanmedj.2015.150148. Epub 2016 May 1.

23.

Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Blakeley JO, Coons SJ, Corboy JR, Kline Leidy N, Mendoza TR, Wefel JS.

Neuro Oncol. 2016 Mar;18 Suppl 2:ii13-ii20. doi: 10.1093/neuonc/nov291. Review.

24.

Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E; National Cancer Institute PRO-CTCAE Study Group.

Health Qual Life Outcomes. 2016 Feb 19;14:24. doi: 10.1186/s12955-016-0426-6.

25.

Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer.

Wang XS, Shi Q, Dougherty PM, Eng C, Mendoza TR, Williams LA, Fogelman DR, Cleeland CS.

Oncology. 2016;90(3):127-35. doi: 10.1159/000443377. Epub 2016 Feb 17.

26.

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.

Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ.

Blood Cancer J. 2016 Feb 12;6:e396. doi: 10.1038/bcj.2016.4.

27.

Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Arnold B, Mitchell SA, Lent L, Mendoza TR, Rogak LJ, Barragán NM, Willis G, Medina M, Lechner S, Penedo FJ, Harness JK, Basch EM; PRO-CTCAE Spanish Translation and Linguistic Validation Study Group.

Support Care Cancer. 2016 Jul;24(7):2843-51. doi: 10.1007/s00520-015-3062-5. Epub 2016 Feb 2.

PMID:
26838022
28.

Favorable patient reported outcomes following IMRT for early carcinomas of the tonsillar fossa: Results from a symptom assessment study.

Gunn GB, Hansen CC, Garden AS, Fuller CD, Mohamed AS, Morrison WH, Frank SJ, Beadle BM, Phan J, Chronowski GM, Sturgis EM, Lewis CM, Lu C, Hutcheson KA, Mendoza TR, Cleeland CS, Rosenthal DI.

Radiother Oncol. 2015 Oct;117(1):132-8. doi: 10.1016/j.radonc.2015.09.007. Epub 2015 Sep 21.

29.

Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group.

JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639. Erratum in: JAMA Oncol. 2016 Jan;2(1):146.

30.

Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA.

Biol Blood Marrow Transplant. 2016 Feb;22(2):226-231. doi: 10.1016/j.bbmt.2015.07.036. Epub 2015 Aug 5.

31.

Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.

Mendoza TR, Wang XS, Williams LA, Shi Q, Vichaya EG, Dougherty PM, Thomas SK, Yucel E, Bastida CC, Woodruff JF, Cleeland CS.

J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22.

32.

Impact of recall period on primary brain tumor patient's self-report of symptoms.

Armstrong TS, Vera-Bolanos E, Acquaye A, Gilbert MR, Mendoza TR.

Neurooncol Pract. 2014 Jun;1(2):55-63. Epub 2014 May 5.

33.

Validation of the MD Anderson Symptom Inventory-Head-and-Neck-Filipino (MDASI-HN-F): clinical utility of symptom screening among patients with head-and-neck cancer.

Bacorro WR, Sy Ortin TT, Suarez CG, Mendoza TR, Que JC.

BMJ Support Palliat Care. 2017 Jun;7(2):140-149. doi: 10.1136/bmjspcare-2014-000787. Epub 2015 May 3.

PMID:
25941198
34.

Automated pain intervention for underserved minority women with breast cancer.

Anderson KO, Palos GR, Mendoza TR, Cleeland CS, Liao KP, Fisch MJ, Garcia-Gonzalez A, Rieber AG, Nazario LA, Valero V, Hahn KM, Person CL, Payne R.

Cancer. 2015 Jun 1;121(11):1882-90. doi: 10.1002/cncr.29204. Epub 2015 Feb 24.

35.

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS.

Cancer. 2015 Apr 1;121(7):1138-46. doi: 10.1002/cncr.29154. Epub 2014 Dec 2.

36.

The symptom burden of treatment-naive patients with head and neck cancer.

Hanna EY, Mendoza TR, Rosenthal DI, Gunn GB, Sehra P, Yucel E, Cleeland CS.

Cancer. 2015 Mar 1;121(5):766-73. doi: 10.1002/cncr.29097. Epub 2014 Nov 4.

37.

Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2.

Walbert T, Mendoza TR, Vera-Bolaños E, Acquaye A, Gilbert MR, Armstrong TS.

J Neurooncol. 2015 Jan;121(2):341-8. doi: 10.1007/s11060-014-1638-4. Epub 2014 Oct 31.

PMID:
25359395
38.

Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).

Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D.

J Natl Cancer Inst. 2014 Sep 29;106(9). pii: dju244. doi: 10.1093/jnci/dju244. Print 2014 Sep.

39.

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ.

Leuk Lymphoma. 2015 May;56(5):1335-41. doi: 10.3109/10428194.2014.956313. Epub 2014 Nov 20.

40.

Response to Lai et al., "development of a symptom index for patients with primary brain tumors".

Armstrong TS, Mendoza TR.

Value Health. 2014 Sep;17(6):752-3. doi: 10.1016/j.jval.2014.06.004. Epub 2014 Jul 17. No abstract available.

PMID:
25237001
41.

Nomogram for predicting symptom severity during radiation therapy for head and neck cancer.

Sheu T, Fuller CD, Mendoza TR, Garden AS, Morrison WH, Beadle BM, Phan J, Frank SJ, Hanna EY, Lu C, Cleeland CS, Rosenthal DI, Gunn GB.

Otolaryngol Head Neck Surg. 2014 Oct;151(4):619-26. doi: 10.1177/0194599814545746. Epub 2014 Aug 7.

42.

Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.

Rosenthal DI, Mendoza TR, Fuller CD, Hutcheson KA, Wang XS, Hanna EY, Lu C, Garden AS, Morrison WH, Cleeland CS, Gunn GB.

Cancer. 2014 Jul 1;120(13):1975-84. doi: 10.1002/cncr.28672. Epub 2014 Apr 7.

43.

Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors.

Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, Cleeland CS.

Cancer. 2014 Feb 1;120(3):425-32.

44.

Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.

Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS.

Clin Cancer Res. 2014 Mar 1;20(5):1366-74. doi: 10.1158/1078-0432.CCR-13-2442. Epub 2014 Jan 14.

45.

Development of the alopecia areata symptom impact scale.

Mendoza TR, Osei JS, Shi Q, Duvic M.

J Investig Dermatol Symp Proc. 2013 Dec;16(1):S51-2. doi: 10.1038/jidsymp.2013.19.

46.

Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data.

Shi Q, Duvic M, Osei JS, Hordinsky MK, Norris DA, Price VH, Amos CI, Christiano AM, Mendoza TR.

J Investig Dermatol Symp Proc. 2013 Dec;16(1):S49-50. doi: 10.1038/jidsymp.2013.18.

47.

The validity and utility of the MD Anderson Symptom Inventory in patients with prostate cancer: evidence from the Symptom Outcomes and Practice Patterns (SOAPP) data from the Eastern Cooperative Oncology Group.

Jones D, Zhao F, Fisch MJ, Wagner LI, Patrick-Miller LJ, Cleeland CS, Mendoza TR.

Clin Genitourin Cancer. 2014 Feb;12(1):41-9. doi: 10.1016/j.clgc.2013.07.003. Epub 2013 Oct 12.

48.

The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study.

Cleeland CS, Zhao F, Chang VT, Sloan JA, O'Mara AM, Gilman PB, Weiss M, Mendoza TR, Lee JW, Fisch MJ.

Cancer. 2013 Dec 15;119(24):4333-40. doi: 10.1002/cncr.28376. Epub 2013 Sep 24.

49.

Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.

Armstrong TS, Wefel JS, Wang M, Gilbert MR, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M.

J Clin Oncol. 2013 Nov 10;31(32):4076-84. doi: 10.1200/JCO.2013.49.6067. Epub 2013 Oct 7.

50.

Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E; NCI PRO-CTCAE Study Group.

Qual Life Res. 2014 Feb;23(1):257-69. doi: 10.1007/s11136-013-0470-1. Epub 2013 Jul 20.

Supplemental Content

Loading ...
Support Center